Antoine Italiano
University of Bordeaux
528 Papers
1.1K Citations
Antoine Italiano is an academic researcher from University of Bordeaux. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 56, co-authored 366 publications. Previous affiliations of Antoine Italiano include Argonne National Laboratory & French Institute of Health and Medical Research.
Chat about Author
Papers
Outcome of Patients with Soft-Tissue Sarcomas: An Age-Specific Conditional Survival Analysis.
Kevin Bourcier,Derek Dinart,Axel Le Cesne,Charles Honoré,Pierre Meeus,Jean-Yves Blay,A. Michot,François Le Loarer,Antoine Italiano +8 more
TL;DR: Conditional survival estimates show clinically relevant variations according to time since first diagnosis in both young and elderly patients with STS, and can help STS survivors adjust their view of the future and STS care providers plan patient follow-up.
Combination of pembrolizumab and metronomic cyclophosphamide in patients with advanced sarcomas and GIST: A French Sarcoma Group phase II trial.
Maud Toulmonde,Nicolas Penel,Julien Adam,Christine Chevreau,Jean-Yves Blay,Axel Le Cesne,Emmanuelle Bompas,Sophie Piperno-Neumann,Sophie Cousin,Thomas Ryckewaert,Alban Bessede,François Ghiringhelli,Thomas Grellety,Marina Pulido,Antoine Italiano +14 more
TL;DR: The results of the first open-label multicentre phase 2 study assessing the anti-PD-1 antibody pembrolizumab in combin...
Phase Ib study of RG7112 with doxorubicin (D) in advanced soft tissue sarcoma (ASTS).
Sant P. Chawla,Jean-Yves Blay,Antoine Italiano,Martin Gutierrez,Axel Le Cesne,Carlos Gomez-Roca,Launce G. Gouw,Margaret von Mehren,Andrew J. Wagner,Robert G. Maki,Brian Higgins,Steven A. Middleton,Gwen Nichols,David Geho,Steven Blotner,Jianguo Zhi,Lin-Chi Chen +16 more
TL;DR: This study evaluated the tolerability of combining D with RG7112 in ASTS patients and pharmacokinetic and pharmacodynamic parameters of the combination and safety, PK and PD, including serum MIC-1 (an indicator of p53 activation), were assessed.
Targetable Alterations in Adult Patients With Soft-Tissue Sarcomas: Insights for Personalized Therapy.
Carlo Lucchesi,Emmanuel Khalifa,Yec'han Laizet,Isabelle Soubeyran,Simone Mathoulin-Pélissier,Christine Chomienne,Antoine Italiano +6 more
TL;DR: Up to 41% of STS harbored at least 1 clinically relevant GA with potential to influence and personalize therapy, and comprehensive genomic profiling can identify novel treatment paradigms to address the limited options and poor prognoses of patients with STS.
Immunologic constant of rejection signature is prognostic in soft-tissue sarcoma and refines the CINSARC signature
François Bertucci,Vincent Niziers,Alexandre de Nonneville,Pascal Finetti,Lénaïg Mescam,Olivier Mir,Antoine Italiano,Axel Le Cesne,Jean-Yves Blay,M. Ceccarelli,Davide Bedognetti,Daniel Birnbaum,Emilie Mamessier +12 more
TL;DR: A robust prognostic clinicogenomic model is built integrating ICR, CINSARC, and pathological type, and suggested differential vulnerability of each prognostic group to different systemic therapies, and identified drug classes potentially able to reverse the expression profile of poor-prognosis tumors.